Compare PFAI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFAI | MDXH |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | Canada | Belgium |
| Employees | 13 | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4M | 41.1M |
| IPO Year | N/A | 2021 |
| Metric | PFAI | MDXH |
|---|---|---|
| Price | $3.60 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 1.7K | ★ 758.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $0.45 |
| 52 Week High | $4.93 | $5.33 |
| Indicator | PFAI | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 18.95 |
| Support Level | $3.56 | N/A |
| Resistance Level | $4.07 | $3.79 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 0.00 | 11.12 |
Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware, and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups, and is developing a hydroponic growing system for urban farms. Geographically, the company generates the majority revenue from Canada, followed by New Zealand.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.